EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Impact of P‐gp inhibition on systemic exposure of pralsetinib and dosing considerations

Julia Suchomel iD, Priya Agarwal, Doreen Anders, Kevin Hughes, Yang Tang iD, Rucha Sane, Astrid Scalori, Sunil Sharma, Sravanthi Cheeti

Clinical and Translational Science · 2024

DOI: 10.1111/cts.13818 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Julia Suchomel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Cyclosporine, Drug Interactions, Healthy Volunteers. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Genentech Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A study to determine the impact of cyclosporine (Neoral), an inhibitor of P‐gp, on the pharmacokinetics of pralsetinib (trade name GAVRETO ® ) was conducted in 15 healthy adult volunteers. A single 200 mg dose of pralsetinib was administered orally alone and in combination with cyclosporine with a 9‐day washout between treatments. Co‐administration with cyclosporine resulted in a clinically relevant increase in pralsetinib maximum plasma concentration ( C max ) and area under the plasma concentration–time curve extrapolated to infinity (AUC 0–∞ ) with associated geometric mean ratios (GMRs) and 90% confidence intervals (CIs) of 148% (109, 201) and 181% (136, 241), respectively. These findings provide insight into concomitant dosing of pralsetinib with inhibitors of P‐gp given the increases in pralsetinib exposure observed when administered with cyclosporine. Based on these results, co‐administration of pralsetinib with P‐gp inhibitors is not recommended. In the event that co‐administration cannot be avoided, it is recommended that the dose of pralsetinib be reduced.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclosporineDrug InteractionsHealthy VolunteersHumansMaleAdultFemaleYoung AdultArea Under CurveMiddle AgedAdministration, OralATP Binding Cassette Transporter, Subfamily B, Member 1Dose-Response Relationship, DrugBenzimidazoles

Substanzen

CyclosporineAZD 6244ATP Binding Cassette Transporter, Subfamily B, Member 1Benzimidazoles

Autor:innen und Institutionen

  • Genentech, Inc., South San Francisco, California, USA.
  • Hoffman-La Roche, Basal, Switzerland.
  • Syneos Health, Raleigh, North Carolina, USA.

ORCID-Profile: Julia Suchomel, Yang Tang

Förderung

  • Genentech Inc

Zitieren

APA

Suchomel, J., Agarwal, P., Anders, D., Hughes, K., Tang, Y., Sane, R., Scalori, A., Sharma, S., & Cheeti, S. (2024). Impact of P‐gp inhibition on systemic exposure of pralsetinib and dosing considerations. Clinical and Translational Science. https://doi.org/10.1111/cts.13818

Vancouver

Suchomel J, Agarwal P, Anders D, Hughes K, Tang Y, Sane R, et al. Impact of P‐gp inhibition on systemic exposure of pralsetinib and dosing considerations. Clinical and Translational Science. 2024. doi:10.1111/cts.13818

BibTeX
@article{Suchomel2024,
  author = {Suchomel, Julia and Agarwal, Priya and Anders, Doreen and Hughes, Kevin and Tang, Yang and Sane, Rucha and Scalori, Astrid and Sharma, Sunil and Cheeti, Sravanthi},
  title = {Impact of P‐gp inhibition on systemic exposure of pralsetinib and dosing considerations},
  journal = {Clinical and Translational Science},
  year = {2024},
  doi = {10.1111/cts.13818}
}
Kostenlos starten →